Use of Open Access Platforms for Clinical Trial Data.

Loading...

Date

2016-03

Journal Title

Journal ISSN

Volume Title

Citation Stats

Attention Stats

Abstract

Department

Description

Provenance

Subjects

Humans, Information Dissemination, Access to Information, Drug Industry, Databases, Factual, Clinical Trials as Topic

Citation

Published Version (Please cite this version)

10.1001/jama.2016.2374

Publication Info

Navar, Ann Marie, Michael J Pencina, Jennifer A Rymer, Darcy M Louzao and Eric D Peterson (2016). Use of Open Access Platforms for Clinical Trial Data. JAMA, 315(12). pp. 1283–1284. 10.1001/jama.2016.2374 Retrieved from https://hdl.handle.net/10161/34265.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Pencina

Michael J Pencina

Adjunct Professor in the Department of Biostatistics & Bioinformatics

Positions

  • Adjunct Professor in the Department of Biostatistics & Bioinformatics
  • Former Chief Data Scientist for Duke Health


Division of Translational Biomedical Informatics


Michael J. Pencina, PhD

Adjunct Professor, Biostatistics & Bioinformatics
Former Chief Data Scientist, Duke Health
Duke University School of Medicine

Michael J. Pencina, PhD, currently serves as UnitedHealth Group chief AI scientist, where he leads data science initiatives to enhance the organization’s innovative use of responsible AI systems that deliver real-world impact at scale for patients, providers, consumers and health plan members.  He is also adjunct professor of biostatistics and bioinformatics at Duke University School of Medicine.  He formerly served as Chief Data Scientist at Duke Health.

Dr. Pencina is an internationally recognized authority in the development, evaluation and responsible application of AI algorithms. His work pioneered new methods for assessment of predictive algorithms and helped establish frameworks for intentional governance of health AI systems. Expert societies and guideline groups have relied on his work to advance best practices for the application of clinical decision support tools in health delivery.  Since 2014, Thomson Reuters/Clarivate Analytics has regularly recognized Dr. Pencina as one of the world’s "highly cited researchers" in clinical medicine and social sciences, with more than 400 publications cited over 150,000 times.

He co-founded the national Coalition for Health AI (CHAI), a multi-stakeholder effort whose mission is to increase trustworthiness of AI by developing guidelines to drive high-quality health care through the implementation of innovative, credible, and transparent health AI systems. He also spearheaded establishing and co-led Duke Health’s Algorithm-Based Clinical Decision Support (ABCDS) Oversight Committee.

Dr. Pencina joined the Duke University faculty in 2013, and served as director of biostatistics for the Duke Clinical Research Institute until 2018. Previously, he was an associate professor in the Department of Biostatistics at Boston University and the Framingham Heart Study, and director of statistical consulting at the Harvard Clinical Research Institute. He received his PhD in Mathematics and Statistics from Boston University in 2003 and holds master’s degrees from the University of Warsaw in actuarial mathematics and business culture.

Email: michael.pencina@duke.edu

Web Sites:  medschool.duke.eduaihealth.duke.eduhttps://scholars.duke.edu/person/michael.pencina

Phone:  919.613.9066

Address:  Duke University School of Medicine; 2424 Erwin Road, Suite 903; Durham, NC 27705

 

Rymer

Jennifer Anne Rymer

Associate Professor of Medicine

Darcy Louzao

Clinical Trials Project Leader III

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.